Form 4: Director Sara Bonstein Receives Xilio Therapeutics Options

Director Sara Bonstein was granted 5,000 stock options in Xilio Therapeutics, Inc. as part of a standard equity compensation arrangement.

Summary

• Director Sara Bonstein received a grant of 5,000 stock options for Xilio Therapeutics, Inc. (XLO) common stock.
• The options have an exercise price of $7.99 per share.
• The grant date for these options is June 11, 2026.
• The options are set to expire on June 10, 2036.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral administrative filing reflecting standard director compensation practices.

Positives

• Aligns director interests with long-term shareholder value through equity-based compensation.

Negatives

• Results in minor potential dilution for existing shareholders upon future exercise of the options.

Risks

• The value of the options is dependent on the future market performance of Xilio Therapeutics common stock.

Future Outlook

The options vest 100% on the earlier of June 11, 2027, or the date of the next annual meeting of stockholders, contingent upon continued service.

Industry Context

StockSavvy.ai notes that equity grants to non-employee directors are a standard corporate governance practice in the biotechnology sector to ensure board alignment with company performance.

Comparison to Industry Standards

• The grant size and vesting schedule are consistent with typical director compensation packages for small-cap biotechnology firms.

Corporate Governance

Stakeholder Impact

• Minor dilution impact on existing shareholders.

Next Steps

• Vesting of the 5,000 stock options on June 11, 2027, or the next annual meeting.

Key Dates

Keywords

Xilio Therapeutics, XLO, Form 4, Insider Trading, Stock Options, Director Compensation